UCB SA (OTCMKTS:UCBJF) Given Consensus Recommendation of “Moderate Buy” by Analysts

UCB SA (OTCMKTS:UCBJF) has been given an average rating of “Moderate Buy” by the seven research firms that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company.

Separately, Piper Sandler reissued a “neutral” rating on shares of UCB in a report on Wednesday, July 22nd.

UCB Price Performance

Shares of UCBJF opened at $280.49 on Wednesday. UCB has a 12-month low of $207.00 and a 12-month high of $345.39. The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19. The stock’s 50-day moving average price is $292.53 and its 200 day moving average price is $300.64.

UCB Company Profile

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.